Laekna Inc., a company incorporated in the Cayman Islands, has announced that it has obtained Investigational New Drug $(IND.AU)$ approval from the U.S. Food and Drug Administration (FDA) for its internally discovered monoclonal antibody, LAE103. This approval marks a significant step in advancing LAE103, an ActRIIB selective antibody, to clinical studies aimed at treating sarcopenic obesity and other muscle-related diseases. The company emphasizes that while this approval is a crucial milestone, there remains the risk that LAE103 may not ultimately be successfully developed and commercialized. The announcement serves to inform shareholders and potential investors of this important business update.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。